Nk/T cell lymphoma
Conditions
Interventions
Case series:Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT
Sponsors
Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. diagnosed NK/T cell lymphoma with the pathologically and immunohistochemically confirmed by tumor tissue; 2. intermediate or high subtype by PINKE risk-factor model with at least one measurable focus; 3. aged >= 16 years; 4. ECOG performance status of <3 with anticipated survival exceeding 3 months; 5. lab tests suitable for chemotherapy.
Exclusion criteria
Exclusion criteria: 1. relapsed or progressed patients treated by Aspargase-contained chemotherapies in recent 6 months; 2. concurrent with HCV or HIV infection; 3. combination with pancreatitis; 4. concurrent with server infection needing ICU care; 5. with serious complications, such as fulminant DIC; 6. important organ failure; 7. pregnant or lactation period; 8. psychonosema; 9. allergy to the drug ofchemotherapy; 10. with secondary tumor need to under operation or chemotherapy in 6 months ahead; 11. in other correlated clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free survival;response rate;toxicity evaluation; | — |
Countries
China
Contacts
Public ContactYao yiyun
Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine
Outcome results
None listed